Seizure disorders, also known as epilepsy, are a group of neurological conditions characterized by recurrent episodes of convulsive, sensory, autonomic, and behavioral disturbances, including loss of consciousness. While seizures can occur due to a variety of causes, including head injury, stroke, and brain tumors, most seizure disorders are classified as idiopathic, meaning the cause is unknown. Seizure symptoms can vary widely, depending on the type of seizure experienced. Generalized seizures, the most common type, can involve full body convulsions and loss of consciousness. Focal seizures, which are seen less frequently, begin in a specific part of the brain and may involve body movements such as clenching of the teeth, lip smacking, and rapid eye blinking. Absence seizures, commonly seen in children, are brief episodes of unconsciousness that can be mistaken for daydreaming. Treatment for seizure disorders typically involves antiepileptic medications that are used to control seizures and minimize their frequency and severity. Dietary therapies, including those involving the ketogenic diet, have also been used to reduce seizure activity. Surgery is sometimes recommended if medications do not adequately control seizures or if the seizure activity originates from a single part of the brain that can be safely removed. It can take time for people living with seizure disorders to find an effective treatment. During this period, people with epilepsy can experience anxiety, stress, and depression.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom